Lexicon Pharmaceuticals (LXRX) Income towards Parent Company (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Income towards Parent Company data on file, last reported at -$996000.0 in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$996000.0, up 96.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 86.35% YoY), and the FY2025 annual result was -$48.9 million, up 75.19% from the prior year.
• Income towards Parent Company grew to -$996000.0 in Q1 2026 per LXRX's latest filing, from -$14.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $3.7 million in Q2 2025 and troughed at -$63.7 million in Q3 2024.
• A 5-year average of -$31.2 million and a median of -$31.4 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company slumped 123.42% in 2023, then surged 106.75% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$31.4 million in 2022, then plunged by 48.93% to -$46.7 million in 2023, then gained by 29.95% to -$32.7 million in 2024, then jumped by 54.85% to -$14.8 million in 2025, then jumped by 93.26% to -$996000.0 in 2026.
• Business Quant data shows LXRX's Income towards Parent Company at -$996000.0 in Q1 2026, -$14.8 million in Q4 2025, and -$12.2 million in Q3 2025.